Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.

Slides:

Advertisements

Similar presentations

Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,

Advertisements

TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.

Understanding patents & medicine access the WTO, free trade agreements & patent law.

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.

Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.

Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.

Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.

Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

A revised framework for global medicine access Sanjay Basu Reblaw X.

Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.

The Politics of Patents Jason Andrews. The Access GAP 2.4 Million people died of AIDS in sub Saharan Africa in 2002 – yet only 50,000 in the region had.

Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.

Assessing the impact of TRIPS-plus provisions on Public Healh: Lessons from Latin America David Vivas Eugui WTO Public Forum CSEND Roundtable.

1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

The TRIPs Amendment: Developments and implications Tralac/ Comomonwealth post Hong Kong Conference 10 April 2006 Tenu Avafia UNDP.

1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.

A very short introduction to patents & access to medicines.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

Issues Pertinent for Action in the South Presentation to Partners in Population and Development: Meeting on Accelerating Essential Health Commodity Security.

Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.

Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.

TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

D OHA N EGOTIATIONS & I NDIA P resenters * E vgeniya Burova * M ohini Patel.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,

Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.

WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,

1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.

Intellectual Property Rights in the WTO CARSTEN FINK The WTO and the Doha Development Agenda Washington, DC, April 26, 2005.

ASEAN regional workshop on bilateral Free Trade Agreements Francisco Rossi. IP and access to drugs capacity building project. UNDP - International poverty.

Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November

The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.

UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.

© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.

TRIPS+ provisions in FTAs and the implications for access to medicines Sanya Smith Third World Network 27 August 2005.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

Agreement on TRIPS TRIPS Agreement  When the WTO was established, it led to 18 specific agreements to which all members need to adhere. Members necessarily.

TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.

Civil Society Strategy Meeting on the Future of Access to Medicines Bangkok, December 2011 Intellectual Property/Trade and Access to Medicines Session.

IMPACT OF THE DOHA DECLARATION November 14, 2011 Carlos M. Correa.

Ellen ‘t Hoen Médecins sans Frontières

WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.

Tensions between Brazil and the United States

Access to Medications: An introduction Braveen Ragunanthan Keanan McGonigle Slides prepared by: Alison Case, Education and Advocacy Fellow Katrina Ciraldo,

South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.

Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.

TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.

Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.

AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).

M Forere, lecturer - UKZN.  Tariffs imposed on imports – trade barriers  Article I of GATT – Most Favored Nation (MFN)  Article II of GATS - MFN 

Patents & Public Health

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

WTO and medicines: from Doha to Cancún

Intellectual Property Protection and Access to Medicines

PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES

“ … the individual’s self-assessed state of health … is always the most significant of all of the explanatory variables [associated with individual self-assessed.

WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.

Trade-related policies and access to medicines

Competing in Global Markets

Intellectual Property Rights in Medicines Procurement

Presentation transcript:

Medicine Access: Claims & Data Sanjay Basu

The Framework for Access The pipeline fallacy Patents and pricing

TRIPs measures TRIPs & the WTO Parallel importation Compulsory licensing

What generics help do…

Are generics ‘illegitimate’? The claim: Generic competition will undermine the pharma industry and future R&D TRIPs-plus and Special 301

R&D spending?

Who pays?

A lesson from AIDS drugs

The Doha Declaration – “The TRIPS Agreement does not and should not prevent Members from taking measures to protect public health” – The WTO will operate to facilitate “access to medicines for all” – “We recognize that WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement.”

Doha derailed... USTR (originally with EU and Japanese support) broke initial deadline for negotiations This month: 17-page decision...but existing flexibilities apply New infrastructure being built in southern Africa by Brazil

Things to watch out for... “The documents show that the trade association, the Pharmaceutical Research and Manufacturers of America, known as PhRMA, will spend at least $150 million in the coming year.” “The drug trade group plans to spend $1 million for an "intellectual echo chamber of economists”--a standing network of economists and thought leaders to speak against federal price control regulations through articles and testimony, and to serve as a rapid response team.“ “At least $2 million, and perhaps $2.5 million, in payments to research and policy organizations, "to build intellectual capital and generate a higher volume of messages from credible sources" sympathetic to the industry.” “In addition, the budget sets aside $17.5 million to fight price controls and protect patent rights in foreign countries and in trade negotiations.” “$9.4 million for public relations, including "$1 million for inside-the- Beltway advertising, $555,000 for placement of op-eds and articles by third parties," $600,000 for polling, $1.3 million for local publicity in 15 states and $680,000 for media relations consultants.”

Things to watch out for... Attaran, Gillespie-White and “off-patent essential medicines” Roger Bate and “Africa Fighting Malaria” DiMasi’s “$800 million” R&D figure “Data exclusivity”

The new USTR proposals: New “AIDS Czar” Chile – CAFTA – FTAA – PPP Singapore – Indonesia/Thailand – ASEAN SACU Projected December completion date

More information… ****Dying for Growth: Global Inequality and the Health of the Poor (Kim et al., 2000) ****Pathologies of Power: Health, Human Rights and the New War on the Poor (Farmer, 2003) Siamese Tragedies: Development & Disintegration in Modern Thailand (Bello et al., 1998) Global Intellectual Property Rights: Knowledge, Access and Development (Drahos & Mayne, 2002)